Endometrial Serous Adenocarcinoma Clinical Trial
Official title:
Randomized Phase III Trial of Cisplatin and Tumor Volume Directed Irradiation Followed by Carboplatin and Paclitaxel Vs. Sandwich Therapy of Carboplatin and Paclitaxel Followed by Tumor Volume Directed Irradiation Then Further Carboplatin and Paclitaxel
To determine if treatment with cisplatin and radiation followed by carbo and taxol reduces the rate of recurrence when compared to sandwich therapy.
To determine if treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles (experimental arm) reduces the rate of recurrence (increases recurrence-free survival) when compared to sandwich therapy (control arm). To determine if treatment with cisplatin and volume-directed radiation followed by carboplatin and paclitaxel for 4 cycles (experimental arm) reduces the rate of death (increases survival) when compared to sandwich therapy (control arm). To compare the regimens with respect to tolerability and acute and late adverse effects of therapy. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01010126 -
Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer
|
Phase 2 | |
Completed |
NCT01935973 -
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT03660826 -
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
|
Phase 2 | |
Completed |
NCT01642082 -
Dalantercept in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01440998 -
Dasatinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
|
Phase 1 | |
Completed |
NCT02728258 -
Copanlisib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00977574 -
Paclitaxel, Carboplatin, and Bevacizumab or Paclitaxel, Carboplatin, and Temsirolimus or Ixabepilone, Carboplatin, and Bevacizumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01225887 -
Nintedanib in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 | |
Completed |
NCT01005329 -
Intensity-Modulated Radiation Therapy, Cisplatin, and Bevacizumab Followed by Carboplatin and Paclitaxel in Treating Patients Who Have Undergone Surgery for Endometrial Cancer
|
Phase 2 | |
Recruiting |
NCT05256225 -
Testing the Addition of Trastuzumab or Trastuzumab/Pertuzumab to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
|
Phase 2/Phase 3 | |
Withdrawn |
NCT03836157 -
Mirvetuximab Soravtansine (IMGN853) and Bevacizumab in Patients With Endometrial Cancer
|
Phase 2 | |
Suspended |
NCT04585958 -
Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Endometrial Cancer
|
Phase 1 | |
Active, not recruiting |
NCT02142803 -
TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00807768 -
Pelvic Radiation Therapy or Vaginal Implant Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With High-Risk Stage I or Stage II Endometrial Cancer
|
Phase 3 | |
Completed |
NCT01307631 -
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT02065687 -
Paclitaxel and Carboplatin With or Without Metformin Hydrochloride in Treating Patients With Stage III, IV, or Recurrent Endometrial Cancer
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT02874430 -
Metformin Hydrochloride and Doxycycline in Treating Patients With Localized Breast or Uterine Cancer
|
Phase 2 | |
Completed |
NCT01210222 -
Trebananib in Treating Patients With Persistent or Recurrent Endometrial Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00942357 -
Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer
|
Phase 3 | |
Completed |
NCT01132820 -
Cediranib Maleate in Treating Patients With Recurrent or Persistent Endometrial Cancer
|
Phase 2 |